NCT05415644已完成1 期
Study of the Bioequivalence and Food Effects of HRX0701 Tablets in Healthy Subjects
Shandong Suncadia Medicine Co., Ltd.1 个研究点 分布在 1 个国家目标入组 78 人开始时间: 2022年7月5日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 78
- 试验地点
- 1
- 主要终点
- The PK parameters of retagliptin and metformin in the blood plasma on fasting and after meals peak concentration (Cmax)
研究概览
简要总结
To evaluate the bioequivalence of a single oral dose of HRX0701 tablets and the reference formulations retagliptin phosphate tablets and metformin hydrochloride tablets in healthy subjects in the postprandial state; To evaluate the pharmacokinetic effects of a high-fat diet on retagliptin and metformin after a single oral administration of HRX0701 tablets in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female subjects aged 18 to 45 years (both ends of the value, subject to the signing of informed consent).
- •Male weight ≥ 50.0 kg, female weight ≥ 45.0 kg, and body mass index (BMI): 19~26 kg/m2 (including both ends).
- •Based on medical history, comprehensive physical examination, laboratory tests, 12-lead ECG, chest x-ray, vital signs, etc., the researchers determined that the subjects met the health criteria.
- •Voluntarily sign an informed consent form prior to the commencement of activities related to this trial, be able to understand the procedures and methods of this trial, and be willing to complete this trial in strict compliance with the clinical trial protocol.
排除标准
- •Have a history of any clinically serious disease or a disease or condition that the researcher believes may affect the results of the test, including but not limited to circulatory system, endocrine system, nervous system, digestive system, urinary system or blood, immune, psychiatric and metabolic disease history.
- •People with allergies, including those who are explicitly allergic to the research drug or any ingredient in the research drug, allergic to any food ingredients or have special requirements for diet, and cannot comply with the unified diet.
- •Those who have undergone any surgery within 3 months before screening, or who have not recovered after surgery, or who may have surgery or hospitalization plans during the estimated trial period.
- •Have taken any prescription drugs, over-the-counter drugs, Chinese herbal medicines or dietary supplements within 2 weeks before the screening period;
- •Those who have consumed grapefruit or fruit juice products within 2 days before administration, any food or beverage containing caffeine (such as coffee, tea, chocolate, cola or other carbonated drinks containing caffeine, etc.), xanthine foods or alcohol.
- •The researcher determines that the subject has a medical condition that affects the absorption, distribution, metabolism and excretion of the drug or can reduce compliance or the researcher deems inappropriate.
- •Screening those who have participated in clinical trials of any drug or medical device within 3 months before screening.
- •Those who donated blood (or lost blood) within 3 months before screening and donated blood (or lost blood) ≥ 400 mL, or received blood transfusions.
- •Those who plan to receive live (attenuated) vaccines during the trial.
- •Have a birth plan at the end of the screening to follow-up period, or refuse to use medically approved contraception.
- •Smokers (average of 5 cigarettes or more per day).
- •An average daily intake of more than 25 g of alcohol in the 1 month prior to screening (e.g., 750 mL of beer, 250 mL of wine, or 50 mL of low-grade liquor);
- •Drug abusers or drug urine screening test positive.
- •Positive for hepatitis B surface antigen (HBsAg) within 1 month before screening or screening period, or positive for anti-hepatitis C virus (HCV), or positive for human immunodeficiency virus (HIV), or positive for syphilis antibody.
- •12-lead electrocardiogram (ECG) shows abnormalities and is of clinical significance.
- •There are any abnormal laboratory test values that are clinically significant by the researchers; (Note: For abnormal laboratory tests with clinical significance, if there is a clear and reasonable reason, the retest can be retested within one week, and the retest results can be used to determine whether the subject meets the conditions).
- •Subjects may not be able to complete this study for other reasons or those whom the researchers believe should not be included.
研究组 & 干预措施
Bioequivalence study part
Experimental
干预措施: hrx0701 tablets、Metformin hydrochloride tablets、Retagliptin phosphate tablets (Drug)
Food impact study part
Experimental
干预措施: hrx0701 tablets (Drug)
结局指标
主要结局
The PK parameters of retagliptin and metformin in the blood plasma on fasting and after meals peak concentration (Cmax)
时间窗: day 1 to day 18
PK parameters AUC0-∞ in the postprandial plasma of subjects in postprandial plasma
时间窗: day 1 to day 18
The PK parameters of retagliptin and metformin in the blood plasma on fasting and after meals area under the drug-time curve (AUC0-∞)
时间窗: day 1 to day 18
PK parameters Cmax, in the postprandial plasma of subjects in postprandial plasma
时间窗: day 1 to day 18
PK parameters AUC0-t in the postprandial plasma of subjects in postprandial plasma
时间窗: day 1 to day 18
The PK parameters of retagliptin and metformin in the blood plasma on fasting and after meals reach peak time (Tmax)
时间窗: day 1 to day 18
The PK parameters of retagliptin and metformin in the blood plasma on fasting and after meals area under the drug-time curve (AUC0-t)
时间窗: day 1 to day 18
次要结局
- apparent clearance (CL/F)(day 1 to day 18)
- terminal phase half-life (t1/2)(day 1 to day 18)
- The main metabolites of retagliptin acid PK parameters Cmax(day 1 to day 18)
- The main metabolites of retagliptin acid AUC0-∞(day 1 to day 18)
- Adverse events(day 1 to day 25)
- retagliptin and metformin in plasma on fasting and after meals(day 1 to day 18)
- The main metabolites of retagliptin acid AUC0-t(day 1 to day 18)
- Apparent distribution volume (Vz/F)(day 1 to day 18)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A HR20031 BE Study on Healthy SubjectsType 2 DiabetesNCT05682495Shandong Suncadia Medicine Co., Ltd.96
已完成
1 期
Food-effect on PK and PD of Single Oral Dose of HIP1601 in Healthy Male SubjectsHeathy VolunteerNCT03882112Hanmi Pharmaceutical Company Limited24
已完成
1 期
To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative BioavailabilityGraft-versus-host DiseaseNCT05856058Jiangsu HengRui Medicine Co., Ltd.16
已完成
1 期
Food Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mgHealthyNCT00647881Mylan Pharmaceuticals Inc75
已完成
不适用
A Bioequivalence Study Comparing a Single Oral Intake of an Imported PROBUCOL Tablet(Lorelco) With a Marketed PROBUCOL Tablet(Chang Tai) in Chinese Healthy VolunteersChinese Healthy VolunteersNCT02196805Otsuka Beijing Research Institute120